| ABT – 751 |
Antimitotic sulfonamide |
Abbott |
II |
| ABX-EGF |
Anti-EGF monoclonal antibody |
Abgenix and Amgen |
II |
| Adenazole |
Nucleotide analog |
Valeant Pharmaceuticals |
I |
| Alimta (pemetrexed sodium) |
Multi-targeted folate inhibitor |
Eli Lilly |
II |
| Alkylade (0-6-benzylguanine) |
AGT inhibitor |
Access Oncology, Pacific Pharmaceuticals |
II |
| Alvac-CEA vaccine |
Vaccine |
Aventis Pasteur and Therion Biologics |
II |
| |
|
|
|
| Angiozyme |
Anti angiogenic ribozyme |
Chiron |
II |
| APC 8024 |
HER2 antagonist |
Dendreon |
I |
| AP 5346 |
DACH polymer palatinate |
Access Oncology |
I |
| Aptosyn (exisuland) |
Selective apoptotic antineoplastic drug (SAAND) |
OSI Pharmaceuticals |
II |
| Aroplatin |
Liposomal platinum |
Antigenics |
II |
| Avastin (bevacizumab) |
Anti-VEGF |
Genentech |
Approved 10-05-05, first line |
| Avicine (CTP-37) |
Vaccine |
SuperGen |
III |
| Bay 43-9006 |
Raf kinase inhibitor |
Bayer |
II |
| BMS-247616(S-1) |
Fluorouracil prodrug |
Bristol-Myers Squibb |
II |
| Cantuzumab mertasense |
MoAB |
Immunogen |
I |
| Canvaxin |
Vaccine |
CancerVax |
II |
| CEA-B7.1 |
Vaccine |
Sanofi-Aventis |
|
| Cofactor |
Biomodulator |
Adventrx Pharmaceuticals |
II |
| Collidem |
Vaccine |
IDM Biotech |
I |
| E7070 |
Sulfonamide |
Eisai |
II |
| Edotecarin |
Topoisomerase I inhibitor |
Pfizer |
III |
| EKB-569 |
EGFR receptor kinase inhibitor |
Wyeth |
II |
| EP-2101 |
DNA vaccine |
Epimmune |
I |
| Epothilone D |
Cytotoxic macrolide |
Hoffman LaRoche Kosan Pharmaceuticals |
II |
| GBC-590 |
Lechtin inhibitor |
Glyco Genesy |
I |
| GCS-100 |
Galactin binding carbohydrate |
GlycoGenesys |
II |
| Genasense (oblimersen) |
Antisense |
Genta |
! |
| GTI-2040 |
Antisense |
Lorus Therapeutics |
II |
| IMC-1C11 |
MoAb against VEGF-KDR |
Imclone |
I |
| Immu-111 (labetuzumab-1-131) |
CEA labeled MoAB |
Immunomedics |
I |
| Iressa (gefitinib) |
EGFR inhibitor |
Astra Zeneca |
II |
| Mapatumumab (HGS-ERR1) |
MoAB |
Human Genomics |
II |
| Oncophage (HSPPC-96) |
Heat Shock Protein vaccine |
Antigenics |
II |
| Orathecin (rubitecan) |
Topoisomerase I inhibitor |
SuperGen |
II |
| Panitumumab (rHuMAb-EGFr) |
Monoclonal antibody Anti-EGRF |
Amgen Abgenix |
II |
| PTK787/ZK 222584 (vatalanib) |
Tyrosine kinase inhibitor against VEGF pathway |
Novartis and Berlex Laboratories |
III |
| Tarceva (erlotinib) |
EGFr inhibitor |
Genetech OSI |
II |
| Taxoprexin (docosahexaenoic acid-paclitaxel) |
Taxane |
Protarga |
II |
| Telcyta (TLK286) |
Selective apopototic agent |
Telik |
II |
| Tezacitabine |
Nucleoside analogue |
Chiron |
II |
| Theratope |
Vaccine |
Biomira |
II |
| Thymitaq (nolatrexed) |
Thymidylate synthase inhibitor |
Eximias Pharmaceutical |
II |
| Thymectacin (NB1011) |
MDR enzyme catalyzed therapeutic activator |
New Biotics Elan |
I |
| Velcade (bortezomib) |
Proteosome inhibitor |
Millenium OrthoBiotech |
III |
| Xyotax (polyglutamate paclitaxel) |
Taxane |
Hoffman LaRoche Cell Therapeutics |
II |
Patient Home
Meeting Calendar
